Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by Neos Therapeutics, Inc. (“Neos” or the “Company”)
(NASDAQ: NEOS).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased shares of Neos during the Class Period, please contact
Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd
Floor, Irvine, CA 92612, by telephone: 949-419-3834, or by email at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
The investigation will focus on the Company’s October 19, 2015, report
that the U.S. Food and Drug Administration has identified deficiencies
in the Company’s new drug application for Cotempla XR-ODT that preclude
discussion of labeling and marketing requirements at this time.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone:
949-419-3834, or by email at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151020006924/en/
Copyright Business Wire 2015